Tumor-specific idiotype vaccines in the treatment of patients with B- cell lymphoma - Long-term results of a clinical trial

Blood

Volumn 89, Issue 9, 1997, Pages 3129-3135

  Hsu, Frank J ^a   Caspar, Clemens B ^a   Czerwinski, Debra ^a   Kwak, Larry W ^a   Liles, Tina Marie ^a   Syrengelas, Athanasia ^a   Taidi Laskowski, Behnaz ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN; TUMOR ANTIGEN; TUMOR VACCINE;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TARGET CELL; TREATMENT OUTCOME; VACCINE PRODUCTION;

EID: 0031007771     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.9.3129     Document Type: Article

References (25)

1. Levy R, Hatzubia A, Brown S, Maloney D, Dilley J: Immunoglobulin idiotype: A tumor-specific antigen for human B-cell lymphomas, in Rosenberg SA, Kaplan HS (eds): Malignant Lymphomas: Etiology, Immunology, Pathology, Treatment, New York, NY, Academic, 1982, p 95
2. Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R: Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: Characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 4:191, 1985
3. Lynch RG, Rohrer JW, Odermatt B, Gebel HM, Autry JR, Hoover RG: Immunoregulation of murine myeloma cell growth and differentiation: A monoclonal model of B cell differentiation. Immunol Rev 48:45, 1979
4. Stevenson GT, Elliott EV, Stevenson FK: Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: A therapeutic target. Fed Proc 36:2268, 1977
5. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R: Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 145:1029, 1990
6. Tao MH, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755, 1993
7. Chen TT, Tao MH, Levy R: Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 153:4775, 1994
8. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517, 1982
9. Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, Levy R: Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 80:1502, 1992
10. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73:651, 1989
11. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R: A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65:1349, 1985
12. Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J, Levy R: Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 312:1658, 1985
13. Levy R, Levy S, Cleary ML, Carroll W, Kon S, Bird J, Sklar J: Somatic mutation in human B cell tumors. Immunol Rev 96:43, 1987
14. Bahler DW, Levy R: Clonal evolution of a follicular lymphoma: Evidence for antigen selection. Proc Natl Acad Sci USA 89:6770, 1992
15. George AJ, Folkard SG, Hamblin TJ, Stevenson FK: Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol 141:2168, 1988
16. Campbell MJ, Esserman L, Levy R: Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol 141:3227, 1988
17. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
18. Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R: Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann NY Acad Sci 690:385, 1993
19. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The non-Hodgkin's lymphoma pathologic classification project. Cancer 49:2112, 1982
20. Carroll WL, Thielemans K, Dilley J, Levy R: Mouse × human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods 89:61, 1986
21. Hsu FJ, Levy R: Preferential use of the VH4 immunoglobulin gene family by diffuse large cell lymphoma. Blood 86:3072, 1995
22. Vuist WM, Levy R, Maloney DG: Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 83:899, 1994
23. Allen PD, Bustin SA, Macey MG, Johnston DH, Williams NS, Newland AC: Programmed cell death (apoptosis) in immunity and haematological neoplasia. Br J Biomed Sci 50:135, 1993
24. Nelson EL, Li XB, Hsu FJ, Kwak LW, Levy R, Clayberger C, Krensky AM: Tumor-specific, cytotoxic T lymphocyte response after "idiotype" vaccination for B cell, non-Hodgkin's lymphoma. Blood 88:580, 1996
25. Hsu FJ, Benike C, Fagnoni F, Lilies TM, Cerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996